⚡
CHARGED ALPHA
Stock Detail
Stock Library / ABBV
ABBV Healthcare Latest YouTube: Q1 2026

AbbVie Inc.

Live stock metrics, chart context, a quarter-by-quarter YouTube archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest on YouTube Company Website Back to Library

Library coverage

Quarters tracked
1
YouTube quarters live
1
Latest video
Q1 2026
YouTube available
Yes
Current price
$208.38
-0.50 (-0.24%)
Trailing / Forward P/E
87.55x
Forward: 12.95x
Market cap / Volume
—
Volume: —
Revenue / Earnings Growth
10.0%
Earnings: 8354.5%
Margins
34.1% op
Gross: 71.6% · Net: 6.9%
Balance sheet
0.67x current
Debt / Equity: -2064.1
52-week range / Beta
$168.54 - $244.81
Beta: 0.36
Analyst target
$249.00
Upside: 19.5%
Cash / shareholder return
4.98% FCF yield
Dividend yield: 3.18%

Company context

Industry: Drug Manufacturers - General
Country: United States
Employees: —
Price to book: -112.71x
Return on equity: 6225.0%
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Price chart

Market context for ABBV

Competitive view

ABBV vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

AbbVie Inc.
ABBV
YouTube
Latest video
Q1 2026
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Johnson & Johnson
JNJ
YouTube
Latest video
Q1 2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Merck & Co.
MRK
YouTube
Latest video
Q1 2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Market Cap
More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.
ABBV
$368.57B
AbbVie Inc.
JNJ
$564.35B
Johnson & Johnson
MRK
$294.39B
Merck & Co.
Trailing P/E
Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.
ABBV
87.5x
AbbVie Inc.
JNJ
21.2x
Johnson & Johnson
MRK
16.4x
Merck & Co.
Forward P/E
Forward P/E is often a better read on what investors are paying for the next year of earnings power.
ABBV
12.9x
AbbVie Inc.
JNJ
18.4x
Johnson & Johnson
MRK
12.2x
Merck & Co.
Revenue Growth
Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.
ABBV
10.0%
AbbVie Inc.
JNJ
9.9%
Johnson & Johnson
MRK
5.0%
Merck & Co.
Earnings Growth
Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.
ABBV
8354.5%
AbbVie Inc.
JNJ
-52.9%
Johnson & Johnson
MRK
-19.3%
Merck & Co.
Operating Margin
Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.
ABBV
34.1%
AbbVie Inc.
JNJ
26.7%
Johnson & Johnson
MRK
32.8%
Merck & Co.
Gross Margin
Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.
ABBV
71.6%
AbbVie Inc.
JNJ
68.0%
Johnson & Johnson
MRK
77.2%
Merck & Co.
Net Margin
Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.
ABBV
6.9%
AbbVie Inc.
JNJ
21.8%
Johnson & Johnson
MRK
28.1%
Merck & Co.
Return on Equity
ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.
ABBV
6225.0%
AbbVie Inc.
JNJ
—
Johnson & Johnson
MRK
36.9%
Merck & Co.
Free Cash Flow Yield
Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.
ABBV
5.0%
AbbVie Inc.
JNJ
3.4%
Johnson & Johnson
MRK
4.0%
Merck & Co.
Debt to Equity
Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.
ABBV
-2064.10x
AbbVie Inc.
JNJ
60.50x
Johnson & Johnson
MRK
95.96x
Merck & Co.
Current Ratio
A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.
ABBV
0.67x
AbbVie Inc.
JNJ
1.03x
Johnson & Johnson
MRK
1.54x
Merck & Co.
Beta
Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.
ABBV
0.36
AbbVie Inc.
JNJ
0.33
Johnson & Johnson
MRK
0.28
Merck & Co.
Dividend Yield
Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.
ABBV
3.2%
AbbVie Inc.
JNJ
2.2%
Johnson & Johnson
MRK
2.8%
Merck & Co.
Analyst Upside
Higher analyst upside suggests the Street still sees room between current price and consensus fair value.
ABBV
19.5%
AbbVie Inc.
JNJ
7.2%
Johnson & Johnson
MRK
9.0%
Merck & Co.

YouTube timeline

Quarterly archive for ABBV

Each row is one quarter. Only the YouTube link is shown here for now.

Q1 2026
Video live
Published youtube complete
Quarterly earnings-analysis entry for AbbVie Inc.. Use the YouTube link on the right to jump straight into that quarter's video when it is live.
YouTube